Literature DB >> 21694816

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

João Carlos Correia de Sa1, Laura Airas, Emmanuel Bartholome, Nikolaos Grigoriadis, Heinrich Mattle, Celia Oreja-Guevara, Jonathan O'Riordan, Finn Sellebjerg, Bruno Stankoff, Karl Vass, Agata Walczak, Heinz Wiendl, Bernd C Kieseier.   

Abstract

As more investigations into factors affecting the quality of life of patients with multiple sclerosis (MS) are undertaken, it is becoming increasingly apparent that certain comorbidities and associated symptoms commonly found in these patients differ in incidence, pathophysiology and other factors compared with the general population. Many of these MS-related symptoms are frequently ignored in assessments of disease status and are often not considered to be associated with the disease. Research into how such comorbidities and symptoms can be diagnosed and treated within the MS population is lacking. This information gap adds further complexity to disease management and represents an unmet need in MS, particularly as early recognition and treatment of these conditions can improve patient outcomes. In this manuscript, we sought to review the literature on the comorbidities and symptoms of MS and to summarize the evidence for treatments that have been or may be used to alleviate them.

Entities:  

Keywords:  clinical medicine; comorbidity; multiple sclerosis; neurology; review; signs and symptoms; therapy

Year:  2011        PMID: 21694816      PMCID: PMC3105633          DOI: 10.1177/1756285611403646

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  277 in total

Review 1.  Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation?

Authors:  L Yap; A Kouyialis; T R K Varma
Journal:  Br J Neurosurg       Date:  2007-08       Impact factor: 1.596

Review 2.  Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature.

Authors:  Amanda R O'Brien; Nancy Chiaravalloti; Yael Goverover; John Deluca
Journal:  Arch Phys Med Rehabil       Date:  2008-04       Impact factor: 3.966

3.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

Review 4.  Pathophysiology and management of bowel dysfunction in multiple sclerosis.

Authors:  P H Wiesel; C Norton; S Glickman; M A Kamm
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-04       Impact factor: 2.566

5.  Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.

Authors:  Steven A Kaplan; Evan R Goldfischer; William D Steers; Marc Gittelman; Masakazu Andoh; Sergio Forero-Schwanhaeuser
Journal:  Aging Male       Date:  2010-06       Impact factor: 5.892

Review 6.  Vertigo: epidemiologic aspects.

Authors:  Hannelore K Neuhauser; Thomas Lempert
Journal:  Semin Neurol       Date:  2009-10-15       Impact factor: 3.420

Review 7.  Palliative treatment of dysphonia and dysarthria.

Authors:  Seth M Cohen; Alphi Elackattu; J Pieter Noordzij; Michael J Walsh; Susan E Langmore
Journal:  Otolaryngol Clin North Am       Date:  2009-02       Impact factor: 3.346

8.  Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis.

Authors:  Jagannadha R Avasarala; Anne H Cross; Kathryn Trinkaus
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

Review 9.  Deep brain stimulation and tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 10.  Tremor in multiple sclerosis.

Authors:  Marcus Koch; Jop Mostert; Dorothea Heersema; Jacques De Keyser
Journal:  J Neurol       Date:  2007-02-21       Impact factor: 4.849

View more
  21 in total

1.  Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.

Authors:  Verena Isabell Leussink; Leila Husseini; Clemens Warnke; Erasmia Broussalis; Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

2.  A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.

Authors:  Andrew D Goodman; Theodore R Brown; Randall T Schapiro; Michael Klingler; Ron Cohen; Andrew R Blight
Journal:  Int J MS Care       Date:  2014

Review 3.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  Reliability and validity of the Eating Assessment Tool-10 (Greek adaptation) in neurogenic and head and neck cancer-related oropharyngeal dysphagia.

Authors:  Athanasia Printza; Athanasios Kyrgidis; Elena Pavlidou; Stefanos Triaridis; Jannis Constantinidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-17       Impact factor: 2.503

5.  Biomechanical analysis of spasticity treatment in patients with multiple sclerosis.

Authors:  Michael Wininger; William Craelius; Jill Settle; Stephanie Robinson; Bobbi Isaac; Heidi Maloni; Minoosh Moradi; Nicki Ann Newby; Mitchell Wallin
Journal:  Ther Adv Neurol Disord       Date:  2015-09       Impact factor: 6.570

6.  Validity and Reliability of the Turkish Version of the Multiple Sclerosis-Related Symptom Checklist.

Authors:  Zeliha Tülek; Cansu Polat; Murat Kürtüncü; Mefkure Eraksoy
Journal:  Noro Psikiyatr Ars       Date:  2016-04-26       Impact factor: 1.339

7.  Exercise in multiple sclerosis -- an integral component of disease management.

Authors:  Andrea Döring; Caspar F Pfueller; Friedemann Paul; Jan Dörr
Journal:  EPMA J       Date:  2011-12-24       Impact factor: 6.543

8.  Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.

Authors:  Heidi Crayton; Matthew Sidovar; Stanley Wulf; Amy Guo
Journal:  Patient       Date:  2015-06       Impact factor: 3.883

9.  Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment.

Authors:  Mena Al-Ani; Noha Mousaad Elemam; Ibrahim Y Hachim; Tom K Raju; Jibran Sualeh Muhammad; Mahmood Y Hachim; Riyad Bendardaf; Azzam A Maghazachi
Journal:  J Inflamm Res       Date:  2021-06-17

Review 10.  Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

Authors:  Jose Eustasio Meca-Lallana; Rocío Hernández-Clares; Ester Carreón-Guarnizo
Journal:  Brain Behav       Date:  2015-07-14       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.